Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0O0AH
|
||||
Former ID |
DIB006196
|
||||
Drug Name |
MIRFENTANIL HYDROCHLORIDE
|
||||
Synonyms |
A-3508 hydrochloride; ANQ-3508 HCl; Mirfentanil hydrochloride < Rec INNM; OHM-10579 (free base); N-(1-Phenethyl-4-piperidinyl)-N-(2-pyrazinyl)furan-2-carboxamide hydrochloride
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89] | Discontinued in Phase 2 | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C22H25ClN4O2
|
||||
Canonical SMILES |
C1CN(CCC1N(C2=NC=CN=C2)C(=O)C3=CC=CO3)CCC4=CC=CC=C4.Cl
|
||||
InChI |
1S/C22H24N4O2.ClH/c27-22(20-7-4-16-28-20)26(21-17-23-11-12-24-21)19-9-14-25(15-10-19)13-8-18-5-2-1-3-6-18;/h1-7,11-12,16-17,19H,8-10,13-15H2;1H
|
||||
InChIKey |
KVCOVXMNIYUKBS-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 119413-53-5
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Mu-type opioid receptor | Target Info | Agonist | [2], [3] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Estrogen signaling pathway | |||||
Morphine addiction | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Enkephalin release | |||||
Pathway Interaction Database | IL4-mediated signaling events | ||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | TCR Signaling Pathway | ||||
GPCRs, Class A Rhodopsin-like | |||||
Peptide GPCRs | |||||
Opioid Signalling | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003921) | ||||
REF 2 | Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J Pharmacol Exp Ther. 1991 Aug;258(2):502-10. | ||||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.